Risk Attitudes and Personality Traits Predict Perceptions of Benefits and Risks for Medicinal Products: A Field Study of European Medical Assessors  by Beyer, Andrea R. et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 1 – 9 91098-3015$36.00 – s
Published by Elsevie
http://dx.doi.org/10
E-mail: a.r.m.bey
* Address corresp
Groningen 9713, Thjournal homepage: www.elsevier .com/ locate / jva lHealth Policy AnalysisRisk Attitudes and Personality Traits Predict Perceptions of
Beneﬁts and Risks for Medicinal Products: A Field Study of
European Medical Assessors
Andrea R. Beyer, MPH1,2,*, Barbara Fasolo, PhD3, P.A. de Graeff, MD1, H.L. Hillege, MD1
1Department of Epidemiology, University Medical Center of Groningen, Groningen, The Netherlands; 2European Medicines Agency,
London, UK; 3London School of Economics and Political Science, London, UKA B S T R A C TBackground: Risk attitudes and personality traits are known predic-
tors of decision making among laypersons, but very little is known of
their inﬂuence among experts participating in organizational decision
making. Methods: Seventy-ﬁve European medical assessors were
assessed in a ﬁeld study using the Domain Speciﬁc Risk Taking scale
and the Big Five Inventory scale. Assessors rated the risks and beneﬁts
for a mock “clinical dossier” speciﬁc to their area of expertise, and
ordinal regression models were used to assess the odds of risk
attitude or personality traits in predicting either the beneﬁt or the
risk ratings. Results: An increase in the “conscientiousness” score
predicted an increase in the perception of the drug’s beneﬁt, and male
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greater risks. Conclusions: Medical assessors perceive the beneﬁts
and risks of medicines via a complex interplay of the medical
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research in this area is needed to determine how these potential
biases are managed within the regulatory setting.
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Medicinal products in Europe are regulated within a complex
organizational structure encompassing more than 40 national
competent authorities (NCAs) and relying on the expertise of 4500
experts or medical assessors throughout the European Union [1].
A substantial part of the assessment is under the responsibility of
the medical assessors who work individually, or within groups, in
the NCAs to evaluate the beneﬁts and risks of medicinal drugs. In
the ﬁeld of risk research, there are several well-established
ﬁndings that may be relevant to decision making for the regu-
lation of medicines: 1) that beneﬁt perception is the inverse of
risk perception; 2) that the personality taxonomy from the Big
Five Inventory (BFI) may intersect with risk attitudes and explain
differences in risk taking; and 3) that risk attitudes (risk seeking,
risk neutral, risk averse) are important descriptors for the shape
of a decision-maker’s utility function underlying his or her
choices [2–4]. A full discussion of each of the above-mentioned
ﬁndings is beyond the scope of this article; however, a briefsummary of the literature and references to more detailed
publications are provided below.
Alhakami and Slovic have observed that laypersons have a
negative correlation between beneﬁts and risks in that an activity
or technology judged high in beneﬁt is judged low in risk and vice
versa [5]. An inverse relationship between beneﬁt and risk
perception implies the use of a heuristic, a subconscious rule of
thumb that simpliﬁes decision making by considering only a
subset of the available information when arriving at a decision.
The work of Gigerenzer and Brighton [6] and others [7,8] support
the view of heuristics as an efﬁcient means for managing
uncertainty because it minimizes the need for complex compu-
tations when assessing situations and in many cases allows one
to arrive at a similar level of accuracy as logic-laden decisions.
There may, however, be instances when the application of a rule
of thumb or a heuristic such as beneﬁt-high/risk-low may be
inappropriate given that medicines can have both increased
beneﬁts and increased risks. Evidence of the use of such a
heuristic among assessors could indicate the introduction ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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of interest to determine whether a beneﬁt/risk heuristic, such as
found among laypersons, is also used by assessors of medicinal
drugs. Personality traits are known indicators of risk taking.
Persons with higher levels of the traits extraversion and open-
ness to experience tend to increase risk taking whereas persons
with higher levels of the traits conscientiousness, neuroticism,
and agreeableness decrease risk taking [8,9]. Personality traits are
considered to be very relevant for optimizing organizational
performance because they have been found to predict creativity
and generation of superior ideas when an ‘optimal’ balance of
personality traits is achieved within working teams [10]. The
concept of risk attitudes (risk seeking, risk neutral/tolerant, and
risk averse), when translated into the drug regulatory context,
could imply that an assessor who is risk averse may be willing to
give up the beneﬁt a drug could provide to avoid the uncertainty
regarding long-term adverse effects, whereas a risk-seeking
assessor may be willing to accept some risks to avoid the sure
loss of the drug not reaching the market. A risk-neutral/tolerant
assessor may be seen as having an impartial view with a
willingness to accept some degree of risk in every situation
[2,11]. The risk attitude most often assigned to medical regulators
is one of risk aversion [12,13]; however, there is no concrete
evidence that medical regulators are uniformly risk averse.
Despite its appeal, the term “risk attitude” as a stable individual
trait (e.g., a person who exhibits a risk-averse utility function does
not like to take risks) has had limited empirical support [4,14,15].
Works from Weber et al. [16] and others [14] have shown that
individuals are not stable in their attitudes toward risk and may
shift from being risk neutral to risk seeking depending on the
domain (e.g., health vs. ﬁnance). Weber et al.’s [16] research,
however, has also shown that an individual’s perception of the
riskiness of a situation may be the lever that shifts risk attitude
from averse to seeking; therefore, identiﬁcation of a stable
perception, if such exists, may be of great value in understanding
individual or group decisions under situations of risk.
The research on beneﬁt/risk heuristics, personality traits, and
risk attitudes has been predominantly carried out among lay-
persons; experts have rarely been included in these studies
primarily because of the assumption that given their expertise
they consider only objective data when making judgments of risk
and are not inﬂuenced by other factors [17,18]. There is growing
evidence to contradict this view, and the authors direct readers to
the work of Sjoberg [19] and others [20–22]. In 2009, the European
Medicines Agency (EMA), the central body for regulating medi-
cines in Europe, launched the EMA Beneﬁt-Risk Methodology
Project to assess the applicability of decision support tools within
the regulatory environment [23–25]. Medical assessors in ﬁve
European countries participated in ﬁeld tests of methods aimed
at improving the transparency of decision making [26,27]. One
case study, not originally planned at the onset of the project, was
the market authorization of the H1N1 (swine ﬂu) vaccine. At the
time, there was a genuine public health concern regarding the
global impact of an impending contagious and sometimes fatal
disease, and a decision regarding the market authorization of the
vaccine was urgently needed. This, coupled with the lack of data
on the efﬁcacy and safety of the vaccine, created a highly charged
environment. Consistent with the objectives of the EMA Beneﬁt-
Risk project, senior administrators at the EMA undertook to
participate in a multicriteria decision analysis workshop (exter-
nal to the normal decision-making process) to clarify their
individual attitudes toward the beneﬁts and risks of early or late
approval of the vaccine. The result was a decision model that
increased transparency of the assumptions regarding the number
of expected fatalities if the decision was advanced or postponed.
Although the ﬁnal decision regarding the market authorization of
the swine ﬂu vaccine was not taken during this process, the useof this methodology aided in defusing the tensions surrounding
the decision by highlighting differences in risk attitudes among
the participants and facilitating a more structured discussion of
the implications to approve or not approve the vaccine [28].
Not all regulatory decisions are as charged as that of the swine
ﬂu vaccine, that is, a heightened emotional situation due to the
potential for global fatalities with limited available data and short
time period within which to consider the decision. This is not the
only situation in which it may be appropriate to apply tools that
support the regulatory process and remove the potential for the
introduction of biases in the decision making. If medical asses-
sors, like laypersons, are inﬂuenced by factors external to the
scientiﬁc data even when working within their area of expertise,
then tools such as multicriteria decision analysis or other
structured approaches to decision making should be used to
support their work.
In this study, we aimed to examine the risks and beneﬁts of
medicinal drugs as perceived by expert regulators and to assess
the inﬂuence of personality traits and risk attitudes on their
perceptions. Using Weber’s risk attitudes across domains as a
measure of stable risk attitudes, our hypothesis is that assessors
use the “beneﬁt perception is the inverse of risk perception”
heuristic and that personality traits and risk attitudes that
indicate a propensity for greater risk taking among laypersons
will also be found to indicate greater risk taking among assessors.
Therefore, the objectives of this study were to 1) describe the
distribution of risk attitudes among medical assessors, 2) meas-
ure their personality traits and cross-domain risk attitudes, 3)
measure the correlation between beneﬁt ratings and risk ratings
of a medicinal product, and 4) predict the beneﬁt and risk ratings
of a medicinal product using the measured personality traits and
risk attitudes.Methods
The study was implemented as a Web-based questionnaire and
launched between June 2010 and October 2010. Medical assessors
from nine European NCAs were identiﬁed by their agency and
invited to participate. Demographic data were collected covering
sex, country, age, education level, years in regulatory role, clinical
area of cardiology, central nervous system, and oncology (clinical
efﬁcacy, clinical safety, nonclinical), and therapeutic area of
expertise: central nervous system, cardiovascular, and oncology.
Data were collected in three phases, with each phase lasting
approximately 6 weeks: Phase 1: Demographic data, Domain
Speciﬁc Risk Taking (DOSPERT) scale [29]; Phase 2: Drug Case
Study using a mock “clinical dossier”; and Phase 3: The Big Five
Jackson Inventory personality test [30].
DOSPERT Scale
A number of scales have been developed to capture risk attitudes
or behavior, but the DOSPERT scale was found to be the most
appropriate for the aims of this study because it captures
attitudes toward risk taking within several domains (social,
ﬁnancial, health/safety, recreational, and ethical) that encompass
general life situations. In addition, the DOSPERT scale captures
not only the attitude toward several types of activities within
domains, but also the measurement of an individual’s perception
of the riskiness and beneﬁts of that activity.
The description of the DOSPERT scale provided by the authors
is as follows: The risk-taking responses of the 30-item version of
the DOSPERT scale evaluate behavioral intentions—or the like-
lihood with which respondents might engage in risky activities—
originating from ﬁve domains of life (i.e., social, ﬁnancial, health/
safety, recreational, and ethical), using a seven-point rating scale,
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items include “Disagreeing with an authority ﬁgure on a major
issue” (Social), “Investing 10% of your annual income in a new
business venture” (Financial), “Engaging in unprotected sex”
(Health/Safety), “Taking a weekend sky-diving class” (Recrea-
tional), and “Having an affair with a married man/woman”
(Ethical). The risk perception and the beneﬁt perception scales pose
the same questions as found in the risk taking scale, but here the
aim is to evaluate the respondents’ assessment of the riskiness or
the beneﬁts of each activity, using a seven-point rating scale,
ranging from 1 (Not at all risky) to 7 (Extremely Risky) (17) and 1 (Not
at all beneﬁcial) to 7 (Extremely Beneﬁcial). Only the risk taking and
risk perception scales of the DOSPERT scale were included in the
present study. The addition of the beneﬁt perception scale was
felt to be too burdensome for the assessors given the length of
the questionnaire. In addition, the beneﬁt perception scale and
the risk taking scale of the DOSPERT scale may be highly
correlated because willingness to engage in an activity may be
dependent on the beneﬁt one perceives for that activity. The
scores of the risk taking scale were added across all items of a
given domain subscale to obtain risk-taking scores. Higher scores
suggest a propensity for greater risk taking in that domain.
Similarly, for the risk perception scale, item ratings are added
across all items of the domain subscale to obtain risk perception
scores and higher scores indicate a greater perception of risk.
Risk attitudes for both the risk taking and risk perception
scales are presented as previously reported by Weber and Milli-
man [31] by domain and across the domains. The authors believe
that both presentations are justiﬁed in that Weber and Milliman
have proposed that a given risk attitude may be reﬂected within a
speciﬁc domain but the measurement across all domains may
reﬂect the general risk attitude (GRA) of a person irrespective of
domain. Within each domain, respondent scores for both the risk
taking and risk perception scales were categorized as risk seek-
ing, risk neutral, and risk averse. Assessors whose subscale score
was 1SD above or below the mean were categorized as risk
seeking or risk averse, respectively; otherwise, they were catego-
rized as risk neutral. For the analyses across domains, two new
descriptors were used to categorize risk attitudes, reﬂecting the
risk taking scale and the risk perception scale: GRA and perceived
risk attitude (PRA). For both the GRA and PRA scales, the risk
attitude of each assessor was classiﬁed as seeking, seeking/
neutral, neutral, neutral/averse, averse, or mixed depending on
her or his risk attitude found previously within each of the
domains. An assessor’s GRA was categorized as seeking if he or
she was identiﬁed as risk seeking for all ﬁve domains on the risk
taking scale. If the assessor was classiﬁed as seeking for up to
three domains and then neutral for the remaining, he or she was
categorized as seeking/neutral. Similarly, for the PRA scale, an
assessor was categorized as perceived neutral if he or she was
neutral for all ﬁve domains on the risk perception scale. In cases
where an assessors moved from risk seeking to neutral, they
were categorized as perceived seeking/neutral. The “mixed”
category identiﬁes those who had no discernible pattern in their
risk attitudes; for example, for one domain they were seeking, for
another domain averse, and for another domain neutral.
Descriptive statistics of the risk taking and risk perception
scores are presented and the correlation between the mean risk
taking and mean risk perception scores by domain were
assessed. Statistically signiﬁcant Spearman correlation coefﬁ-
cients were set a priori at less than 0.05.
Big Five Inventory
Five domains of personality (extraversion, openness, neuroti-
cism, conscientiousness, and agreeableness) have been consis-
tently identiﬁed using various instruments over several decadesand across many cultures and is therefore a highly regarded
taxonomy [32–34]. The Big Five Inventory scale used in this area
of research is a self-reported 44-item questionnaire to which
respondents are asked to indicate whether they strongly dis-
agree, disagree, are neutral, agree, or strongly agree. An example
of the description for openness would include “I have a rich
vocabulary,” “I have a vivid imagination,” “I have excellent ideas”
[30,35]. Mean scores and SDs for each trait are presented. Higher
scores within the domains indicate a greater propensity for the
personality trait being measured.
Mock Clinical Dossiers
In the second phase of the study, assessors were given a mock
“dossier” speciﬁc to their therapeutic area of expertise (cardiology,
central nervous system, and oncology). The cardiology product
was indicated for the treatment of atrial ﬁbrillation; the central
nervous system product was indicated for the treatment of neuro-
pathic pain; and the oncology product was indicated for the
treatment of non–small cell lung cancer. Data for the mock
dossiers were adapted from the original product dossiers, day 80
assessment reports, and European Public Assessment Reports [36].
The result was a shortened version of a real dossier, with product-
identifying data (e.g., drug name, manufacturer, and dates)
removed or substituted. The assessors were asked to review the
dossier and to give their perceptions by rating the medicinal
product on two dimensions, risk and beneﬁt. Both ratings used a
Likert-like scale ranging from 1 to 7; for the risk dimension, the
question was “How risky is this product?” Possible risk ratings
ranged from 1 (not at all risky) to 7 (extremely risky). For the beneﬁt
dimension, the question was “How beneﬁcial is this product?”
Beneﬁt ratings ranged from 1 (not at all beneﬁcial) to 7 (extremely
beneﬁcial). The assessors were constrained not to consult with their
colleagues because the aim of the study was to collect their
individual beneﬁt and risk perceptions of the medicinal products.
Model Building
Ordinal regression models were used to evaluate the relation-
ship between the rating of beneﬁts and risks for a medicinal
product (one product in each of the disease areas previously
mentioned), BFI traits, and risk attitudes from the DOSPERT
scale. Ordinal regression models are an extension of the
general linear model to ordinal categorical data. This method
is very useful in social sciences in which data are often
captured as ordinal variables, limiting the usefulness of linear
models that require interval variables. The ordinal model tests
the probability of any category of the independent variables
being in a particular category of the dependent variable or
lower, compared with a reference group. Negative parameter
estimates indicate lower scores for the beneﬁt or risk ratings,
whereas positive estimates indicate choosing higher scores.
For both the GRA and the PRA, the category with the largest
proportion of assessors was the seeking-neutral category and
this was therefore chosen as the reference category.
Because of limited published data on personality traits
and experts, several models were evaluated responding to
our research objectives. To determine which of the BFI
dimensions was most relevant to this analysis, bivariate
analyses were conducted using a backwards stepwise regres-
sion selection procedure between the beneﬁt ratings and the
ﬁve dimensions of the BFI.’ please insert next sentence ‘A
similar procedure was conducted for the risk ratings and the
BFI dimensions. At each iteration of the model, the BFI
dimension with the lowest nonstatistically signiﬁcant Wald
statistic was dropped. Assessors reviewed dossiers relevant to
their area of expertise; therefore, a variable, denoting the three
Table 1 – Demographic characteristics.
Variable Characteristic Frequency
Sex Male 38
Female 37
Age (y) Between 20 and 29 1
Between 30 and 39 22
Between 40 and 49 30
Between 50 and 59 18
>60 3
Professional qualiﬁcations MD 27
MD/PhD 11
PhD 19
PhD/Pharm 3
Pharmacist 10
Other 5
Role in NCA CHMP member 6
Internal assessor 57
External assessor 9
Other 3
Years of regulatory experience by country o5 y 5þ y
France 2 8
Spain 4 3
The Netherlands 8 3
United Kingdom 4 6
Germany 3 7
Austria 9 1
Italy 10 0
Ireland 0 3
Portugal 1 3
CHMP, Committee for Medicinal Purposes for Human Use; NCA, National Competent Authority.
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model building. In previous research, sex has been found to be
predictive of risk perception and so was also included in the
models. Previous work in this area has shown a correlation
between willingness to engage in risky activities depending on
how risky the activity is perceived; therefore, separate models
evaluating the GRA and the PRA were constructed.
Following the bivariate analysis described above, separate mod-
els were built for beneﬁt ratings and risk ratings. Beneﬁt ratings were
regressed on the BFI personality traits identiﬁed from the bivariate
analysis along with the GRA categories, sex, and therapeutic area. A
forward and backwards stepwise regression selection method was
used to determine the ﬁnal model with the best model ﬁt [37].
Variables with nonstatistically signiﬁcant estimates (40.05) were
removed at each iteration. The evaluation of the beneﬁt ratings and
the PRA categories, sex, and therapeutic area followed the same
model-building approach as above. This process was replicated for
building the models for the risk ratings. All parameter estimatesTable 2 – Descriptive statistics of DOSPERT scale—Risk ta
Domain N Mean  SD
Social mean score 75 5.3707  .78685
Financial mean score 75 2.3344  1.13292
Health safety mean score 75 2.4200  0.96771
Recreational mean score 75 2.9542  1.16136
Ethical mean score 75 1.8813  0.76816
Valid N (listwise) 75
DOSPERT, Domain Speciﬁc Risk Taking; SE, standard error.with statistically signiﬁcant results at the less than 0.05 level are
reported along with data for model ﬁt. The authors are aware that
the use of stepwise regression methods has several limitations and
that there are alternatives to this approach (e.g., testing the ﬁnal
model in an independent sample), but given the peculiarity of the
study sample, that is, the limited availability of European medical
assessors, the uniqueness of the sample population, and the
number of variables included for testing (DOSPERT, Big Five taxon-
omy), the chosen approach appeared to be the most pragmatic. All
statistical analyses were conducted using SPSS 18.Results
Demographic Characteristics
Of the 80 assessors enrolled in the study, 75 (94%) responded in
phase 1, while 59 (73%) assessors completed phases 2 and 3. Noking by domain.
Skewness Kurtosis
Statistic SE Statistic SE
0.392 .277 0.251 .548
1.119 .277 1.612 .548
1.010 .277 0.866 .548
0.423 .277 0.419 .548
1.536 .277 3.594 .548
Table 3 – DOSPERT scale—Risk taking and risk perception within the ﬁve domains.
Domain Risk seeking Risk neutral/tolerant Risk averse
Risk taking Row N ¼ 75 % Row N ¼ 75 % Row N ¼ 75 %
Social 19 25.3 46 61.3 10 13.3
Financial 14 18.7 47 62.7 14 18.7
Health/safety 9 12.0 57 71.0 9 12.0
Recreational 12 16.0 51 68.0 12 16.0
Ethical 14 18.7 53 70.7 8 10.7
Risk perception Row N ¼ 75 % Row N¼75 % Row N¼75 %
Social 9 12.0 53 70.7 13 17.3
Financial 13 17.3 48 64.0 14 18.7
Health/safety 14 18.7 50 66.7 11 14.7
Recreational 13 17.3 46 61.3 16 21.3
Ethical 13 17.3 49 65.3 13 17.3
DOSPERT, Domain Speciﬁc Risk Taking.
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experience, or therapeutic area expertise between dropouts from
phase 1 and those who continued on to phases 2 and 3.
As presented in Table 1, the group was equally balanced by
sex; 31% were between 20 and 39 years old. Many assessors had
multiple educational degrees; 51% of the assessors were medi-
cally qualiﬁed, followed by PhD (29%) and pharmacists (13%).
Assessors within the NCAs generally focus on single area of
expertise. In our sample, most of the assessors were experts in
assessing clinical efﬁcacy (63.8%). Assessors with less than 5
years of experience comprised most of the group (55%).Risk Attitudes among Assessors
The mean scores for the DOSPERT scales (risk taking and risk
perceptions) for the ﬁve domains (social, ﬁnancial, health/safety,
recreational, and ethical) are given in Table 2. When the domain
subscale scores for both risk taking and risk perception scales were
categorized by domain, assessors were predominantly risk neutral/
tolerant, with the remaining assessors evenly distributed among
the other categories (Table 3). When the risk taking scale was
evaluated across the domains as presented in Table 4, 2.5% of the
assessors were risk seeking for all domains, no assessor was risk
averse for all domains, and 15% of the assessors were neutral/
tolerant in their GRA. Similarly, for the risk perception scale, 2.5% of
the assessors were categorized as being “perceived risk seeking” for
all domains and 2.5% were “perceived risk averse” for all domains,
while 17.5% of the assessors were perceived risk neutral/tolerant.
Earlier research has shown a relationship between willingness
to engage in risky activities depending on how risky the activity isTable 4 – DOSPERT scale—Risk attitudes across all doma
Risk attitude categories General risk attitude (from the Risk
subscale)
N ¼ 75 %
Seeking 2 2.
Seeking neutral 26 32.
Neutral 12 15.
Neutral averse 24 30.
Averse 0 0
Mixed 11 13.
DOSPERT, Domain Speciﬁc Risk Taking.perceived. We evaluated this relationship using a correlation
analysis between risk taking in each domain and the correspond-
ing risk perception of the activity. There was a statistically
signiﬁcant inverse relationship between mean risk-taking score
and mean risk-perception score (Table 5) for all domains with the
exception of the social domain. The correlation analysis shows
that the riskier an activity is viewed by the assessors, the less
likely they are to engage in it.Big Five Inventory
The scores for the BFI dimensions were normally distributed,
with the following means and standard deviations: extraversion,
3.3  0.738; conscientiousness, 4.1  0.627; agreeableness, 3.8 
0.443; neuroticism, 2.5  0.704; openness, 3.9  0.461. The
regression coefﬁcient of the bivariate analysis for the BFI dimen-
sions showed only conscientiousness (BFIC) to be predictive of
the beneﬁt rating (0.519; P ¼ 0.027); that is, more conscientious
individuals saw more beneﬁt. Extraversion (BFIE) was found to be
predictive of risk rating (0.406; P ¼ 0.047), in that the more
extraverted assessors saw less risks attached to the drug. All
other BFI dimensions were nonsigniﬁcant and therefore excluded
from further modeling.Distribution and Correlation of Beneﬁt and Risk Ratings
For both the beneﬁt and risk scales, the rating has a normal
distribution, with most of the ratings in the middle of the 1 to 7
range. The ratings were reclassiﬁed from ordinal to interval
variables for the purpose of the correlation analysis, and ains.
Taking Perceived risk attitude (from the Risk
Perception subscale)
N ¼ 75 %
5 2 2.5
5 28 35.0
0 14 17.5
0 25 31.2
2 2.5
8 4 5.0
Table 5 – Correlation results between the DOSPERT
Risk Taking and Risk Perception subscales.
Domain Spearman rho Signiﬁcance (0.05)
Social .149 .203
Financial .343* .003*
Health/safety .357* .002*
Recreational .470* .000*
Ethical .350* .002*
DOSPERT, Domain Speciﬁc Risk Taking.
* Statistically signiﬁcant o0.05.
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and risk ratings was found (0.309; P ¼ 0.017).
Ordinal Regression for the Beneﬁt Rating—GRA, PRA, and
BFIC
It has been shown above that BFIC (conscientiousness) was
predictive of the beneﬁt ratings; the addition of the GRA catego-
ries did not improve the model and was therefore dropped. Sex
differences have been found in many studies in risk taking, and
men in general have been found to be more risk taking and to
perceive fewer risks than do women [38,39]. Sex and therapeutic
area were added to the model, but therapeutic area was not
statistically signiﬁcant and did not improve the model ﬁt and was
therefore removed. With only BFIC and sex in the model, the PRA
categories were added but as with the GRA categories, this
variable was not statistically signiﬁcant. The ﬁnal model was
therefore BFIC (0.497; P ¼ 0.036) and sex (0.594; P ¼ 0.041),
showing that controlling for sex, an increase in the score for
conscientiousness increased the probability of giving higher
beneﬁt scores, and similarly controlling for BFIC, male assessors
gave higher beneﬁt scores than did female assessors (Table 6).
Ordinal Regression for the Risk Rating—GRA, PRA, and BFIE
As above, the starting point for the model structure was the
bivariate analysis with the risk ratings and BFIE (extraversion).
Additional bivariate models for the GRA (χ2 ¼ 1.267; P ¼ 0.867), sex
(χ2 ¼ 0.206; P ¼ 0.650), and therapeutic area were constructed, and
all were shown to be nonpredictive of the risk ratings with the
exception of the therapeutic area (Table 7). Using the model with
therapeutic area as the basic model, the other predictor variables of
interest were again added or dropped depending on whether an
improvement in the model ﬁt was observed. The BFIE and the PRA
categories along with therapeutic area resulted in the most robustTable 6 – Ordinal regression results for the beneﬁt rati
Location Estimate SE
BFIC .497 .237
Male .594 .290
Female 0 –
Model 2 log likelihood
Intercept Only 156.377
Final 147.553
Goodness of ﬁt
Pearson
Deviance
BFIC, Big Five Inventory conscientiousness; SE, standard error.model for predicting the risk ratings (Table 8). Assessors with higher
scores for extraversion were more likely to give lower risk ratings.
Compared with those in the perceived risk seeking-neutral cate-
gory, the neutral-averse, averse, and mixed categories were more
likely to give higher risk ratings, controlling for therapeutic area.Discussion
To our knowledge, this is the ﬁrst study to examine personality
traits and risk attitudes within the pharmaceutical regulatory
network in Europe. The study aims to examine relationship
between risk perception and beneﬁt perception among expert
assessors, as measured by the beneﬁt and risk rating of three
medicinal products. One of our key ﬁndings is that, as for
laypersons, beneﬁts and risks are inversely correlated among
medical assessors. We believe that this is indicative of a heuristic
that may in some cases be veridical, that is, truly reﬂective of the
assessment of the drug but may also lead assessors to negate
true beneﬁts when there are high risks and prevent a balanced
assessment. This inverse relationship of beneﬁts and risks
although providing us with an important view of the mental
model of experts in drug regulation should not serve as the sole
explanation of the assessment process. We argue, on the basis of
results of this study, that the mental models of assessors are far
more complex than previously assumed and that assessors rely
on a complex interplay of risk attitudes and personality traits as
well as the perception of the clinical data when assessing
medicinal drugs.
The results from the DOSPERT scale are useful in countering a
pervasive view that regulators have a shared and stable “risk-
averse” attitude [12,13,40]. Instead, we show that for the domains
measured, assessors are predominantly risk neutral/tolerant and
may even perceive fewer risks than did the sample of US under-
graduates in the Weber et al. [16] study. With the exception of risk
neutral attitude there was no evidence of assessors having a
predominant risk attitude, across all domains; in line with previous
research among laypersons, assessors change their risk attitude,
for example, move from seeking to neutral, or neutral to averse,
depending on the domain. However, it may be that within the risk
attitude categories we have deﬁned using the across-domain
classiﬁcation, there may be a stable risk attitude measurable from
the PRA scale but not from the GRA. Perhaps the GRA with its focus
on behavioral intentions (what is the likelihood of engaging in this
activity?) does not provide a measure of the perceived risks involved
and therefore cannot be used to indicate risk propensity in areas
outside those measured in the DOSPERT scale. Results of the PRA
scale with its focus on risks (how risky is this activity?) acrossngs—BFIC and sex (N ¼ 59).
Wald df Signiﬁcance
4.384 1 0.036
4.191 1 0.041
– 0 –
χ2 df Signiﬁcance
8.825 2 0.012
χ2 df Signiﬁcance
137.060 178 0.990
118.309 178 1.000
Table 7 – Ordinal regression results for the risk ratings—Therapeutic area (N ¼ 59).
Location Estimate SE Wald df Signiﬁcance
Cardiovascular .820 .364 5.079 1 0.024
CNS .728 .338 4.636 1 0.031
Oncology 0 – – 0 –
Model 2 log likelihood χ2 df Signiﬁcance
Intercept only 45.095
Final 38.517 6.579 2 0.037
Goodness of ﬁt χ2 df Signiﬁcance
Pearson 4.757 8 0.783
Deviance 5.181 8 0.738
CNS, central nervous system; SE, standard error.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 1 – 9 9 97domains, however, can be used as an indicator for a stable
personality trait; that is, assessors who can be categorized as
belonging to the seeking-neutral group may be less conservative
that those in the neutral-averse, averse, and mixed groups and
may view other life domains such as assessment of pharmaceut-
ical drugs through this lens.
In the regression analysis, the beneﬁts and risk scores are
explained by individual characteristics, namely, personality traits
and PRA. We have shown in previous work that medical assessors’
risk perception of the three medicinal drugs is speciﬁc to the
situation under review: the type of product, the safety and ethical
concerns, the number of patients potentially impacted by the
adverse effects of the medicinal product, and individual character-
istics such as years of experience as an assessor and sex [20]. It now
appears that personality traits also inﬂuence the perception of
beneﬁts and risks. It is surprising that conscientiousness and
extraversion were the only personality traits from the BFI to be
predictive of the beneﬁt and the risk ratings, respectively, because
the other BFI personality traits (openness, neuroticism, and agree-
ableness) have also been found to be predictive of increasing orTable 8 – Ordinal regression results for the risk ratings—
(N ¼ 59).
Variables Estimate SE
Location
BFIE 0.636 0.230
Cardiovascular 1.246 0.435
CNS 0.684 0.371
Oncology 0 –
Perceived risk attitudes
Seeking 0.304 1.126
Neutral 0.049 0.433
Neutral-averse 0.761 0.358
Averse 2.738 1.225
Mixed 2.728 0.981
Seeking-neutral 0 0
Model 2 log likelihood
Intercept only 177.225
Final 152.865
Goodness of ﬁt
Pearson
Deviance
BFIE, Big Five Inventory extraversion; CNS, central nervous system; SE, sdepressing risk taking in other situations [9]. Conscientiousness is
described as the state of being thorough, careful, or vigilant; it
implies a desire to do a task well and has been found to be
inﬂuential of job performance [41,42]. Therefore, highly conscien-
tious medical assessors may be sensitive to the promise of the
beneﬁts of medicinal products and may place great value on these
aspects when reviewing a medical dossier. Sex was considered a
potential confounder for the relationship between BFIC and the
beneﬁt ratings, and the additive model constructed shows that
indeed both variables contribute to explain the variance in the
beneﬁt ratings. The implication of these results, when the beneﬁt-
risk assessment of medicinal drugs is carried out in teams as it is in
Europe, is that careful thought should be given to the composition
of personality traits and risk attitudes to minimize the negative
effects on team processes of certain personality traits and max-
imize the positive effects of others similar to the consideration
given to the impact of cognitive styles on task execution [10,43].
The authors believe the results show that there is a human
dimension that inﬂuences the perceptions of assessors, which is
not negated simply by their expertise. Assessors are susceptibleBFIE, therapeutic area, and perceived risk attitudes
Wald df Signiﬁcance
7.634 1 0.006
8.210 1 0.004
3.410 1 0.065
– 0 –
0.073 1 0.788
0.013 1 0.910
4.523 1 0.033
4.994 1 0.025
7.731 1 0.005
0 0
χ2 df Signiﬁcance
24.360 8 0.002
χ2 df Signiﬁcance
241.156 252 0.677
148.706 252 1.000
tandard error.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 1 – 9 998to the same failings as laypersons, and this should be acknowl-
edged within the regulatory process. The EMA within the Beneﬁt-
Risk Methodology project has taken steps in this direction, and
the swine ﬂu case study provides one example of an “ideal”
decision-making environment in which “hidden” or subconscious
assumptions are made transparent. This does not mean that the
decision resulting from such a process will be considered “right”
but that every opportunity has been taken to increase the
objectivity of the assessment and decrease the subjectivity
inherent to any human decision-making process.
This study, although providing important additional knowledge
regarding beneﬁt and risk perception of medicinal products and
the interaction with individual and personality traits, has several
limitations. The lack of predictive power of the GRA scale may be
due to the speciﬁc risk-taking activity questions found in the
DOSPERT scale, which may not ﬁt the regulatory domain. In
addition, the long duration of the study necessary for gathering
data in this natural setting resulted in a 77% response rate by the
ﬁnal phase during which the BFI scale measurements were taken.
The resulting sample of assessors within our study appears to be
small; however, the authors hasten to point out that the seemingly
small number of medical assessors is inherent in the design of the
study because we wished to focus on assessors with expertise in
speciﬁc disease areas. Nonetheless, future research could aim to
enroll a larger sample of assessors to test the validity of the results
and also to explore the impact of individual personality traits on
group decision making within the national agencies. Despite the
above- mentioned limitations, our results remain useful for gen-
erating future hypotheses and are among the few available on
expert medical assessors who are, understandably, not readily
accessible for behavioral studies because of the conﬁdential nature
of their work and their heavy work commitments.Conclusions
There is a pervasive belief that decision-making bodies, such as the
European regulatory network, by virtue of their organizational
structure allows for alternative perspectives to be rationally consid-
ered until the optimal decision is reached [44], relying on a hierarchal
bottom-up ﬂow of expert advice and consultation. There is, however,
evidence to contradict this view; that is, real-life organizational
decision making is prone to both cognitive and organizational
limitations and problems of ambiguity, uncertainty, and conﬂict. In
addition, individual risk attitudes and perceptions may negatively
impact the elucidation and consideration of the alternatives [44]. Our
ﬁrst contribution to the extensive body of work on risk perception is
the observation that the perception of beneﬁts that accompany
medicines is as equally complex as that of risks. Similar to lay-
persons, experts view beneﬁts as negatively related to risks. We
encourage the investigation of beneﬁt perception alongside that of
risk perception. A second contribution is that experts perceive the
risks of a hazard via a set of situational and individual characteristics
and therefore the decision of what is risky is a complex interplay of
the situation, their level of expertise, their perception of the risks
involved, and even their sex [4,18,45–47]. The knowledge that
individual characteristics such as personality traits may be inﬂuen-
tial in the way assessors perform their job is not surprising because
like laypersons they are prone to biases and reliance on heuristics;
however, it is important to provide empirical evidence of what
maybe important inﬂuences in the decision-making process and to
challenge those responsible to create diverse decision-making teams
in which individual factors are appropriately balanced. The authors
recommend that medical assessors within the national agencies
participate in an evaluation that assesses their GRAs and their
personality traits. Workshops, similar to those conducted by the
EMA Beneﬁt–Risk Methodology Project to demonstrate theapplication of decision support tools, could be organized within the
NCAs. The aim of the workshop should be to educate medical
assessors on the evidence of risk perception, risk attitude, and
personality trait literature; to demonstrate the impact of their
personality traits on decision making; and to show how decision
support tools can aid the transparency and minimize the impact of
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